Prescribing Paroxetine

Why Paroxetine Still Matters (and Why It's Usually Not Your First Choice)

Paroxetine is a fully effective SSRI with the broadest FDA anxiety franchise of any drug in the class: approved for depression, OCD, panic disorder, social anxiety disorder, generalized anxiety disorder, PTSD, and PMDD. If the only thing that mattered were efficacy at the receptor, paroxetine would be unremarkable: it works about as well as sertraline, citalopram, and escitalopram for depression and anxiety, no better and no worse on the receptor's own terms.

But paroxetine carries a side-effect and pharmacokinetic burden that most other SSRIs don't. It is the worst SSRI for discontinuation syndrome, the worst for sexual dysfunction, among the worst for weight gain, meaningfully anticholinergic, and the strongest CYP2D6 inhibitor in the class, which makes it a drug-interaction magnet. It is the SSRI most people mean when they warn a colleague off "the hard one to stop."

So the honest framing for this guide is different from most. This is not a drug you reach for first. In modern practice, escitalopram and sertraline are the default SSRIs, and paroxetine is a second- or third-line agent, chosen when a patient has a documented past response to it, when a family member responded to it (SSRI response is strongly heritable), or occasionally for its low-dose menopausal hot-flash indication. The thesis of this guide is therefore twofold.

Part 1: Indications: Who Is Paroxetine For?

FDA-Approved Uses

• Major depressive disorder
• Obsessive-compulsive disorder (OCD)
• Panic disorder
• Social anxiety disorder
• Generalized anxiety disorder
• Post-traumatic stress disorder (PTSD): paroxetine and sertraline are the only two SSRIs formally FDA-approved for PTSD
• Premenstrual dysphoric disorder (PMDD)
• Vasomotor symptoms of menopause (hot flashes): as low-dose Brisdelle 7.5 mg qhs, the first non-hormonal agent FDA-approved for this indication (now joined by the neurokinin-3 antagonist fezolinetant and the NK1/NK3 antagonist elinzanetant)

Off-Label / Practical Uses

• Premature ejaculation: the same delayed-orgasm property that is a liability in depression becomes the therapeutic effect here
• Menopausal hot flashes at 7.5–15 mg qhs (reduces hot flashes ~65%, onset within the first week; comparable to escitalopram, citalopram, venlafaxine XR, and desvenlafaxine, no serotonergic agent has a clear edge)

The Anxiety Lore: Correct the Record

Paroxetine has a durable reputation as "the anti-anxiety SSRI." The head-to-head data do not support this. Across more than a dozen large trials, paroxetine performs no better than sertraline, citalopram, venlafaxine, or clomipramine for anxiety, and is consistently outperformed by escitalopram. Its class-level anxiolytic effect size is a modest ~0.3.

Where does the reputation come from? Almost certainly from paroxetine's sedation and fatigue, which patients (and prescribers) mistake for anxiolysis. A drug that makes an anxious person feel calm because tired can feel like it's working on the anxiety when it's really just blunting arousal.

The Formulation Footnote That Should Give You Pause

In the pivotal 12-week depression trials, paroxetine controlled-release (Paxil CR) separated from placebo (60% response vs. 48%; 45% remission vs. 34%), but immediate-release paroxetine in the same program did not reliably beat placebo. That's an unusual and slightly uncomfortable signal for a marketed antidepressant. It doesn't mean IR paroxetine is inert (decades of use say otherwise), but it's a reminder that paroxetine's efficacy is unremarkable, and that dosing to an adequate level matters.

Bipolar Depression: Don't

The large, well-designed STEP-BD trial found that adding paroxetine (or bupropion) to a mood stabilizer did not improve response or remission over placebo. The reassuring part: it also did not increase manic switches or suicidal ideation. But the takeaway is clear: for the great majority of bipolar-depressed patients, paroxetine adds side effects without adding benefit. Optimize the mood stabilizer instead.

Part 2: Before You Start: Candidacy and Workup

Paroxetine requires no routine baseline labs for a healthy adult, and no serum-level monitoring (levels aren't clinically useful). The pre-start work is a conversation and a med-list review, not a blood draw.

Ask Yourself Three Questions Before Writing Paroxetine

1. Is there a specific reason it's paroxetine and not escitalopram/sertraline? A documented prior response, a family member's response, or the hot-flash indication are good reasons. "It's the anxiety one" is not.
2. What's on the med list? Paroxetine's strong CYP2D6 inhibition makes this the single most important pre-start check (see Part 7). Screen for tamoxifen, opioids activated by 2D6 (tramadol, codeine, hydrocodone), TCAs, 2D6-metabolized antipsychotics, atomoxetine, and metoprolol.
3. Who is this patient? Paroxetine is a poor choice in the elderly (anticholinergic burden, falls, hyponatremia), in women planning pregnancy (Category D), in patients where sexual function is a priority, and in anyone with a history of struggling to come off antidepressants.

Get a baseline ECG only if there are QT risk factors (though paroxetine is low QT risk; this concern is mainly citalopram's). Check a sodium at baseline and early if the patient is elderly or on a diuretic (SIADH/hyponatremia risk clusters in the first ~2 weeks). Document a pregnancy plan in any person of childbearing potential.

Who Is a Poor Candidate?

• Anyone for whom a cleaner SSRI (escitalopram, sertraline) would do the same job, i.e., most first-line patients
• Elderly patients, especially with cognitive concerns (anticholinergic and only SSRI with a dementia signal)
• Patients planning conception or likely to become pregnant
• Patients on tamoxifen (breast-cancer prevention/treatment): paroxetine can neutralize it
• Patients with a known history of severe SSRI discontinuation difficulty
• Patients who prioritize sexual function or weight

Part 3: How to Start and Dose

Formulations

• Immediate-release (IR) tablets: the workhorse; cheap generic (roughly $5/month through discount programs)
• Controlled-release (Paxil CR) tablets: a Geomatrix coating delays dissolution to the small intestine (fewer 5-HT₃ receptors), cutting week-1 nausea (14% vs. 23% for IR). The difference disappears by week 2, CR is often not covered by insurance, and, critically, CR has only ~80% of IR's bioavailability, so equivalent doses run ~25% higher (average effective doses in trials: IR ~38 mg, CR ~48 mg). Reserve CR for the patient whose early nausea is a dealbreaker, or the patient whose discontinuation symptoms smooth out on the flatter CR curve.
• Oral suspension: available for fine titration and slow tapers.
• Brisdelle 7.5 mg: a dedicated low-dose IR product for hot flashes.

Starting Dose and Titration

• Give it at night. Paroxetine's sedation makes bedtime dosing the default, and nighttime dosing also blunts the daytime fatigue that patients dislike.
• In panic disorder, start at 10 mg (or lower) and titrate slowly: SSRIs can produce early jitteriness/activation in panic patients, usually within the first 2 weeks, which can be mistaken for worsening anxiety and drive dropout.

The dose-response ceiling is real. A large meta-analysis (Furukawa, Lancet Psychiatry 2019) found SSRI benefit plateaus at low-to-medium doses while side-effect dropouts climb steeply above ~40 mg fluoxetine-equivalents. For paroxetine, that means most patients do best at 20–40 mg; pushing to 50–60 mg buys more side effects far more reliably than more response. OCD is the main exception, where higher, sustained doses are legitimately needed. The usual max is 60 mg; doses above this are rarely justified.

Watch for Nonlinear Kinetics

Paroxetine inhibits its own metabolism (CYP2D6 autoinhibition), so its pharmacokinetics are nonlinear: doubling the dose can more than double the serum level. Practically, the jump from 20 to 40 mg, and especially 40 to 60 mg, can produce a disproportionate rise in exposure and side effects. Titrate in modest steps and give each dose a few weeks before escalating.

Set the Timeline

Block the transporter and you've done nothing yet clinically. Expect ~4 weeks to first meaningful benefit, 6–12 weeks for full effect. Don't judge efficacy, or escalate reflexively, before 4 weeks at a therapeutic dose. Measurement-based care matters: in one 6-month study, remission rates more than doubled (74% vs. 29%) when depression was formally measured at each visit and doses adjusted accordingly, versus clinical impression alone.

Part 4: Monitoring

There are no drug levels and no mandatory labs. Monitoring is clinical, and front-loaded.

Screen for suicidality especially in the first 2–4 weeks and after any dose increase, particularly in patients under 25.

Part 5: Side Effects and How to Manage Them

The governing principle for paroxetine specifically: its side-effect profile is why it's not first-line. Counsel proactively, because forewarned patients tolerate, and unforewarned patients quit (or, worse, quit abruptly).

Sexual Dysfunction: Paroxetine's Signature Liability

This is the standout problem. In patients starting without sexual dysfunction, ~61% developed it on paroxetine at 8 weeks (vs. duloxetine 46%, placebo 29%), and it persisted at 34 weeks (paroxetine ~46%). Paroxetine is consistently rated the worst SSRI for this. Manifestations: decreased libido, delayed or absent orgasm, erectile difficulty, reduced genital sensation, and anhedonia.

Management, in rough order:

1. Wait briefly and reassess: a minority adapt, but don't over-promise this.
2. Lower the dose: often helps without losing efficacy.
3. Switch agents: the highest-yield move. Bupropion, mirtazapine, and vilazodone have far lower sexual burden; if the patient still needs an SSRI, sertraline or escitalopram are better than paroxetine. If two SSRIs cause the same sexual dysfunction, stop trying SSRIs.
4. Add a PDE-5 inhibitor: sildenafil 50–100 mg works for SSRI-induced ED in men and has RCT support in women as well.
5. Adjunct bupropion: commonly used, though the controlled evidence for the sexual-side-effect indication is weak (only one of four subscales reached significance in the key trial). Buspirone (~47 mg/day) has mixed data (a signal in women, none in men).

Discontinuation-Type Symptoms Between Doses

Because of paroxetine's relatively short half-life (~21 hours) and lack of an active metabolite, some patients get interdose withdrawal, classically dizziness starting ~6 hours after a dose. This is a preview of the full discontinuation syndrome (Part 9). One practical fix: switch IR to CR, whose flatter curve can smooth the trough and functionally extend coverage.

Sedation and Fatigue

Paroxetine causes more fatigue and drowsiness than most SSRIs (compounded by its anticholinergic effect). Often mistaken for anxiolysis.

Management:

• Dose at night (usually sufficient).
• If residual daytime fatigue persists, modafinil 200–400 mg/day has RCT support; armodafinil is a longer-acting alternative; psychostimulants (methylphenidate, amphetamine) are options.
• If fatigue is prominent and dose-limiting, this is a reason to switch to a more activating agent (fluoxetine) or a non-SSRI.

Weight Gain

Paroxetine is among the antidepressants most associated with weight gain. The trajectory matters: it's minimal at 3 months but significant by 6 months (more than sertraline or fluoxetine in head-to-head data), so early reassurance can mislead.

Management:

• Counsel on the 6-month trajectory up front.
• Diet, exercise, caloric-beverage awareness.
• Avoid paroxetine in diabetics and the metabolically vulnerable: pick a weight-neutral agent.
• If weight gain becomes a problem, switch (sertraline, fluoxetine, or bupropion are better bets).

GI Effects

• Nausea early (IR 23%, CR 14% at week 1; equalizes by week 2). Take with food; CR helps the first week only.
• Paroxetine is paradoxically linked to anorexia in some analyses despite long-term weight gain: SSRIs cut both ways on appetite across individuals.

Anticholinergic Effects

Alone among the SSRIs, paroxetine has clinically meaningful anticholinergic activity: dry mouth, constipation, urinary hesitancy, and, importantly, cognitive dulling / brain fog. Paroxetine is famous for cognitive side effects within the class. This is a major reason to avoid it in older adults and anyone with cognitive concerns.

Activation / Jitteriness

Early restlessness or agitation, sometimes indistinguishable from akathisia, usually in the first 2 weeks and especially in panic disorder. Start low, titrate slowly, and reassure that it typically passes. A short benzodiazepine bridge is reasonable in panic.

Emotional Blunting / Apathy

Both are dose-related. Patients describe feeling gray, flat, or emotionally muted, or an amotivational apathy. This signals the dose is too high; it is not an expected therapeutic effect.

Management: lower the dose first; if that fails, switch, or add bupropion or a psychostimulant.

Hyponatremia / SIADH

An SSRI class effect, most common in the elderly and usually within the first ~2 weeks. Symptoms: dizziness, fatigue, headache, confusion, and in severe cases seizures. Check a sodium in older or diuretic-treated patients at baseline and early. Usually resolves with discontinuation and fluid management.

Bleeding Risk

SSRIs deplete platelet serotonin and impair aggregation, and paroxetine sits at the high-serotonergic end of the bleeding-risk spectrum (alongside fluoxetine and sertraline). Absolute risk is small (~1 GI bleed per 8,000 prescriptions) but rises sharply with co-factors.

• NSAIDs: 7–15× increased GI-bleed risk: the interaction that matters most.
• Also with warfarin, clopidogrel, aspirin, and around surgery.
• A PPI (e.g., omeprazole) largely neutralizes the excess GI-bleed risk: co-prescribe in high-risk patients.

There is no useful lab to monitor; this is clinical vigilance. Counsel patients on NSAIDs/anticoagulants and flag upcoming surgery.

Falls and Bone Density (Elderly)

SSRIs are associated with decreased bone density and increased fall/fracture risk in older adults, compounded here by paroxetine's sedation, anticholinergic burden, and hyponatremia risk. Another reason paroxetine is a poor geriatric choice.

Part 6: Overdose, Toxicity, and the Boxed Warning

The evidence is genuinely modest (a pooled ~2% vs. ~4% absolute difference in ideation across pediatric trials, with no completed suicides in any trial), and part of the signal may reflect medication prompting disclosure of pre-existing thoughts. But the clinical duty stands: screen closely in the first 2–4 weeks and after increases. Note that paroxetine (with venlafaxine) has shown a somewhat higher pediatric suicidality signal in some analyses, which, along with its withdrawal profile, is why paroxetine is specifically discouraged in children and adolescents; fluoxetine is the preferred pediatric SSRI.

Overdose

Paroxetine is comparatively safe in overdose, like SSRIs generally, far safer than the TCAs it displaced. Isolated overdose usually produces sedation, nausea, and tachycardia; serious toxicity is uncommon. The lethal danger is combinations: with MAOIs or a load of other serotonergic agents (serotonin syndrome), or with drugs whose levels paroxetine raises via CYP2D6 (notably TCAs, where paroxetine-boosted levels can cause fatal arrhythmia).

Serotonin Syndrome

Rare with an SSRI alone; the risk is combinations: MAOIs (absolutely contraindicated), tramadol, other serotonergics (SNRIs, linezolid, St. John's wort), and dextromethorphan (itself a serotonin reuptake inhibitor, and one whose levels paroxetine raises via 2D6). Presentation: agitation, autonomic instability (tachycardia, hyperthermia, hypertension), hyperreflexia and clonus, rigidity, tremor. Management: stop the serotonergic agents, supportive care, benzodiazepines; cyproheptadine and ICU care in severe cases. Triptan co-prescription, despite the old FDA warning, carries a very low real-world risk, roughly 0.6–2.3 cases per 10,000 person-years.

Part 7: Drug Interactions: Paroxetine's Achilles' Heel

This is where paroxetine most differs from the clean SSRIs, and where it most often gets prescribers into trouble. Escitalopram, sertraline (below 150 mg), and citalopram are pharmacokinetically quiet. Paroxetine is not.

Paroxetine Is a Strong CYP2D6 Inhibitor: the Strongest SSRI

It can double or triple the levels of 2D6 substrates and block the 2D6-dependent activation of prodrugs. Screen every med list.

Drugs whose levels paroxetine raises (toxicity risk):

• Tricyclic antidepressants: levels can double/triple; risk of fatal arrhythmia. If combining, use low TCA doses and monitor levels/ECG.
• 2D6-metabolized antipsychotics: aripiprazole, brexpiprazole, risperidone, iloperidone (levels can rise 2–10×) leading to akathisia, EPS, tardive dyskinesia over time. In "schizo-OCD," escitalopram is preferred precisely because it lacks this interaction.
• Atomoxetine: start at the lowest dose, titrate half as fast, target 50–75% lower (poor metabolizers can see ~5× peaks).
• Metoprolol and other 2D6 beta-blockers, propranolol; some antiarrhythmics.
• Methadone: raised levels plus additive QT risk (torsades).
• Dextromethorphan: raised levels and serotonin-syndrome risk.
• Bupropion (itself also a 2D6 inhibitor; mutual effects).

Drugs paroxetine renders ineffective (blocks 2D6 activation of the prodrug):

• Tamoxifen: paroxetine blocks conversion to active endoxifen, potentially compromising breast-cancer treatment/prevention. Avoid paroxetine in any patient on tamoxifen (choose escitalopram, venlafaxine, or citalopram).
• Tramadol, codeine, hydrocodone: reduced analgesia (these are 2D6-activated opioids).

The MAOI Rule

All SSRIs are contraindicated with MAOIs (serotonin syndrome). Washout: at least 2 weeks off paroxetine before starting an MAOI, and at least 2 weeks off an MAOI before paroxetine. Contrast fluoxetine, which needs 5 weeks.

NSAIDs and Anticoagulants

Not a level interaction but a pharmacodynamic bleeding one: NSAIDs raise GI-bleed risk 7–15×. Counsel, prefer acetaminophen for analgesia, and co-prescribe a PPI in high-risk patients.

The Cleaner Alternatives (for Context)

• Escitalopram / citalopram: negligible CYP inhibition; the go-to when interactions matter.
• Sertraline: clean below 150 mg/day; becomes a modest 2D6 inhibitor above that.
• Fluoxetine: like paroxetine, a potent 2D6 (and 2C19) inhibitor, and its effect lingers for weeks after stopping due to its long half-life.
• Fluvoxamine: a potent 1A2/3A4/2C19 inhibitor (the clozapine, caffeine, and warfarin problem child).

Part 8: Special Populations

Pregnancy: the Category D Drug

Paroxetine is the SSRI most encumbered in pregnancy. After a December 2005 FDA advisory flagging cardiac malformations (notably right ventricular outflow defects), paroxetine was moved from Category C to Category D.

What the data actually show: the picture is genuinely mixed. The early signal suggested roughly ~2% cardiac malformation risk vs. ~1% background. Later large analyses (e.g., Einarson et al., ~3,400 exposures) found no significant association with cardiac defects. Any pregnancy carries a 3–5% background anomaly risk, and paroxetine is not a major teratogen, nowhere near thalidomide or isotretinoin.

But the practical reality is asymmetric: because escitalopram and sertraline exist, have more reassuring pregnancy data, and do the same job, there is little reason to start paroxetine in a woman who may conceive. The residual concern isn't worth it when equivalent alternatives are cleaner. Sertraline is the usual reproductive-psychiatry default.

The harder question is the woman already stabilized on paroxetine. Here, weigh against the real danger of relapse: 68% relapse in women who stopped antidepressants around conception vs. 26% who continued (Cohen et al., JAMA 2006); 50% of relapses hit in the first trimester, 90% by the end of the second. Untreated maternal depression carries its own fetal risk (largely via behavioral pathways: missed prenatal care, substance use, poor nutrition).

A reasonable framework:

• Younger patient, fertility window open, stable: consider a pre-conception cross-taper to sertraline, or taper and observe off-medication for ~6 months before trying.
• Older patient, clock ticking, well-controlled only on paroxetine: continuing paroxetine rather than risking destabilization is defensible; this is a shared decision, not the clinician's alone.
• Dosing: use the minimal effective dose (both words matter: a subtherapeutic dose exposes the fetus for no maternal benefit).
• Do not taper off before delivery to "protect" the neonate; it strips the mother's coverage entering the highest-risk postpartum window.

Neonatal Adaptation Syndrome (PNAS): occurs in ~30% of third-trimester-exposed neonates (vs. ~8% unexposed), with jitteriness, increased or decreased tone, grunting/respiratory signs, poor feeding. It is mild, transient, and self-limited (hours to days, no deaths). Coordinate with OB/peds; monitoring mother and baby ~48 hours postpartum is standard. Also counsel on the rare persistent pulmonary hypertension of the newborn (PPHN) associated with late-pregnancy SSRI exposure.

Lactation

Paroxetine has relatively low breast-milk transfer (comparable to sertraline; both are preferred over fluoxetine for breastfeeding on PK grounds). If a mother is already on paroxetine and stable, breastfeeding is generally reasonable with routine infant observation. Coordinate with pediatrics.

Elderly

Paroxetine is a poor geriatric SSRI: the anticholinergic burden (cognitive impairment, urinary retention, constipation), sedation and fall/fracture risk, early hyponatremia, and the observational dementia signal all cluster in exactly this population. If you must use it, start 5–10 mg, titrate slowly to the lowest effective dose, check sodium early, and use NSAIDs cautiously. Better: choose sertraline or escitalopram.

The Dementia Signal: Keep It in Proportion

Paroxetine is the only SSRI with an observational association with dementia; other SSRIs and TCAs do not show it. This is observational, unproven as causal, and confounded, but combined with its anticholinergic pharmacology (anticholinergic burden is a known dementia risk factor), it's a real reason to avoid paroxetine in older adults rather than a proven hazard in everyone.

Pediatric

Avoid paroxetine in children and adolescents. It carries a comparatively higher suicidality signal in youth and the worst withdrawal profile in a population prone to missed doses. Fluoxetine is the best-studied and generally preferred pediatric SSRI.

Renal and Hepatic Impairment

• Renal: SSRIs are minimally renally cleared; paroxetine is safe in renal impairment with, at most, minor caution at the low end of dosing in severe disease. No routine adjustment.
• Hepatic: paroxetine is hepatically metabolized; use lower starting doses and slower titration in significant liver disease and monitor for accumulation.

Part 9: Discontinuation: The Part You Will Actually Manage Most

Why Paroxetine Is the Worst

• Short half-life (~21 hours) with no active metabolite: levels fall fast between and after doses.
• Anticholinergic rebound adds cholinergic-overdrive symptoms on withdrawal.
• The result: abrupt cessation reliably produces symptoms, and long-term high-dose users can suffer for weeks to months.

The Syndrome

Flu-like malaise, dizziness/vertigo, nausea, fatigue, chills, myalgias, irritability, insomnia, vivid dreams, and the hallmark brain zaps (brief, non-painful electric-shock sensations, often with eye movement, distracting, not dangerous). Symptoms are not dangerous but genuinely miserable, and are easily mistaken for relapse (which they are not; they come on far faster and resolve with re-dosing).

Rule of thumb on prevalence (class-wide): ~60% no symptoms, ~35% mild-moderate, ~5% severe, but paroxetine skews the distribution toward the bad end. A patient on paroxetine 10 years who stops cold turkey will almost certainly have severe, prolonged withdrawal.

How to Stop

• Never stop abruptly. Taper always.
• Go slow, and go hyperbolic: the last few milligrams are the hardest, because SERT occupancy falls nonlinearly with dose. Small proportional reductions near the bottom (e.g., 20 → 15 → 10 → 5 → 2.5 mg, or finer) beat fixed decrements. The oral suspension is invaluable for sub-tablet steps.
• Pace it to the patient. A reasonable default is a reduction every 2–4 weeks; long-term users often need months. There is no "too slow."
• Titrate to symptoms: if withdrawal emerges, return to the last comfortable dose and resume tapering more slowly. Done this way, discontinuation essentially never fails.

Two rescue strategies when a paroxetine taper stalls:

1. Switch to CR first and taper the smoother formulation.
2. Bridge to fluoxetine: its long half-life provides a built-in, gentle self-taper; cross to a low fluoxetine dose, stabilize, then taper the fluoxetine (or let it wash out). This is the classic maneuver for the patient who can't get off paroxetine.

How Long to Stay On It

• Single depressive episode: continue ~6 months past remission, then attempt a slow taper. Patients told explicitly to plan on at least 6 months are ~3× more likely to actually continue long enough to benefit.
• Recurrent depression, chronic anxiety, OCD: often long-term or indefinite, in which case the withdrawal problem simply doesn't arise while the patient stays on it.

Part 10: Paroxetine vs the Alternatives

The comparison is unusually one-sided, because paroxetine offers no efficacy advantage and several tolerability disadvantages.

• vs Escitalopram: escitalopram wins on essentially every axis that matters for a first choice: cleaner interactions, less sexual dysfunction, easier discontinuation, better head-to-head anxiety data, and top patient-satisfaction ratings. Escitalopram is the modern default.
• vs Sertraline: sertraline is the reproductive-psychiatry and cardiac-disease favorite (low milk transfer, reassuring pregnancy data), is clean on interactions below 150 mg, and shares paroxetine's PTSD approval with a better side-effect profile. In PTSD specifically, many experts (e.g., Osser) prefer sertraline and actively dislike paroxetine for its sexual effects, weight gain, and sedation.
• vs Fluoxetine: fluoxetine's long half-life makes it forgiving of missed doses and nearly free of discontinuation syndrome (the mirror image of paroxetine), with less weight gain, though it shares the potent 2D6 inhibition and can be activating/insomnia-provoking.
• vs Citalopram: citalopram is interaction-clean but carries the dose-dependent QT caveat (max 20 mg in patients over 60 or hepatic impairment). Paroxetine wins the QT comparison but loses everywhere else.
• vs Fluvoxamine: both are worst-tier for tolerability/interactions; fluvoxamine's problem is 1A2/3A4 inhibition (clozapine, caffeine, warfarin).

Carlat's blunt safety ranking of the SSRIs: best: escitalopram, sertraline. Middle: fluoxetine. Worst: paroxetine, fluvoxamine, citalopram.

So when is paroxetine actually the right call?

• A documented past excellent response to paroxetine specifically (don't fix what isn't broken).
• A family member's clear response to paroxetine (SSRI response is strongly heritable: roughly 42% of response variance is genetic, even without a predictive single-gene test).
• Menopausal hot flashes where low-dose Brisdelle fits, especially alongside depression in a perimenopausal woman (treats both).
• Occasionally, premature ejaculation, where the delayed-orgasm effect is the goal.

Outside those, reach for escitalopram or sertraline.

Mechanism: The Short Version

Paroxetine blocks the serotonin transporter (SERT), the most potent SERT inhibitor among the SSRIs, raising synaptic serotonin. As with all SSRIs, the transporter block is instantaneous but the clinical effect takes ~4 weeks, a lag attributed to gradual desensitization of 5-HT₁A autoreceptors and downstream BDNF-driven neuroplasticity/synaptogenesis. Neuroimaging shows paroxetine dampens limbic activity (amygdala, hippocampus, cingulate) and increases prefrontal activity, a bottom-up normalization of the emotional-regulation circuit.

Two paroxetine-specific pharmacologic quirks drive most of its clinical personality:

1. Muscarinic (anticholinergic) affinity: unique among SSRIs; explains the sedation, cognitive dulling, dry mouth, and constipation.
2. Potent CYP2D6 inhibition with autoinhibition: explains both the drug-interaction burden and the nonlinear kinetics.

For PMDD, note a distinct non-SERT action: SSRIs (paroxetine included) rapidly boost the conversion of progesterone to the calming neurosteroid allopregnanolone (paroxetine lowers the enzyme's activation energy ~10–30×), which likely explains their fast, cycle-timed benefit in premenstrual symptoms.

The Bedside Cheat Sheet